SS31 therapy effectively protects the heart against transverse aortic constriction-induced hypertrophic

Hung-I Lu1, Fan-Yen Lee1, Christopher Glenn Wallace2

  • 1Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineKaohsiung 83301, Taiwan.

Insights

SS31 therapy effectively protected the heart from transverse aortic constriction-induced hypertrophic cardiomyopathy. This peptide treatment reduced cardiac damage, inflammation, and oxidative stress, preserving heart function in mice.

Area of Science:

  • Cardiovascular Biology
  • Pharmacology
  • Mitochondrial Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) is a significant cardiovascular disease.
  • Transverse aortic constriction (TAC) is a common model for inducing cardiac hypertrophy and dysfunction.
  • Mitochondrial dysfunction and oxidative stress play key roles in the pathogenesis of HCM.

Purpose of the Study:

  • To investigate the protective effects of SS31 therapy against TAC-induced cardiac damage.
  • To evaluate the impact of SS31 on cardiac function, cellular damage, and molecular pathways in a mouse model of HCM.

Main Methods:

  • Adult male mice underwent TAC or sham surgery.
  • Mice received SS31 treatment (2.0 mg/kg/day) starting 28 days post-TAC.
  • Cardiac function, histology, and protein expression of inflammatory, apoptotic, fibrotic, and oxidative stress markers were assessed at 60 days.

Main Results:

  • SS31 treatment significantly improved left ventricular ejection fraction and reduced cardiac hypertrophy compared to TAC alone.
  • SS31 suppressed TAC-induced increases in apoptotic nuclei, inflammatory cell infiltration, oxidative stress biomarkers, and fibrosis.
  • SS31 modulated key signaling pathways involved in inflammation, apoptosis, fibrosis, and mitochondrial damage.

Conclusions:

  • SS31 therapy demonstrates significant cardioprotective effects against TAC-induced hypertrophic cardiomyopathy.
  • SS31 mitigates cardiac damage by reducing inflammation, oxidative stress, apoptosis, and fibrosis.
  • SS31 represents a promising therapeutic agent for managing HCM and related cardiovascular conditions.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
534
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
591
Anatomy of the Heart01:27

Anatomy of the Heart

The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
120.7K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
606
Speed of a Transverse Wave01:13

Speed of a Transverse Wave

The speed of a wave depends on the characteristics of the medium. For example, in the case of a guitar, the strings vibrate to produce the sound. The speed of the waves on the strings and the wavelength determine the frequency of the sound produced. The strings on a guitar have different thicknesses but may be made of similar material. They have different linear densities, and the linear density is defined as the mass per length.
One of the key properties of any wave is the wave speed. Light...
4.0K